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Abstract Accumulating evidence suggests that endoge-
nous dopamine may act as a neurotoxin and thereby
participate in the pathophysiology of Parkinson’s disease
(PD). Cyclooxygenase-2 (COX-2) has been implicated in
the pathogenesis of PD due to its ability to generate reactive
oxygen species (ROS). Inhibition of COX-2 leads to
neuroprotection by preventing the formation of dopamine-
quinone. In this study, we examined whether dopamine
mediates 1-methyl-4-phenylpyridinium (MPP+)-induced
toxicity in primary ventral mesencephalic (VM) neurons,
an in vitro model of PD, and if so, whether the protective
effects of COX-2 inhibitors on dopamine mediated MPP+-
induced VM neurotoxicity and VM dopaminergic cell
apoptosis result from the reduction of ROS. Reserpine, a
dopamine-depleting agent, significantly reduced VM neu-
rotoxicity induced by MPP+, whereas dopamine had an
additive effect on MPP+-induced VM neurotoxicity and
VM dopaminergic cell apoptosis. However, inhibition of
COX-2 by a selective COX-2 inhibitor (DFU) or ibuprofen
significantly attenuated MPP+-induced VM cell toxicity
and VM dopaminergic cell apoptosis, which was accompa-
nied by a decrease in ROS production in VM dopaminergic
neurons. These results suggest that dopamine itself mediates
MPP+-induced VM neurotoxicity and VM dopaminergic cell
apoptosis in the presence of COX-2.
Keywords Parkinson’s disease . Ventral mesencephalon .
MPP+ . Apoptosis . Neuroinflammation
Introduction
The primary neuropathological hallmark of Parkinson’s
disease (PD) is the degeneration of dopaminergic neurons
in the substantia nigra pars compacta (SNpc) that project
into the striatum (Fahn and Przedborski 2000). There is
increasing evidence that endogenous dopamine may con-
tribute to neurodegeneration of dopaminergic neurons in
PD (Xu et al. 2002). As a consequence of the degeneration
of nigrostriatal dopaminergic neurons in the SNpc of PD
patients the remaining dopaminergic neurons become
hyperactive in an attempt to restore dopaminergic neuro-
transmission and function (Yu et al. 1996). This then leads
to an increased dopamine turnover (Yu et al. 1996)
consequently resulting in an elevation of hydrogen peroxide
generation as well as neuronal apoptosis (Chu et al. 2006).
Additionally it has been shown that injection of dopamine
into rat striatum causes selective death of dopaminergic
neurons, which can be significantly attenuated by antiox-
idants (Hastings et al. 1996; Hattori et al. 1998).
It has been suggested that oxidative stress might be a key
contributor to the degeneration of nigrostriatal dopaminergic
neurons in PD (Andersen 2004; Jenner 2003), and that
cyclooxygenase-2 (COX-2) can act synergistically to induce
neurodegeneration of dopaminergic neurons (Teismann et al.
2003a, b). COX-2, a pro-inflammatory enzyme which
generates prostaglandins, has been reported to be a key
culprit in mediating 1-methyl-4-phenyl-1,2,3,6-tetrahydro-
peridine (MPTP)-induced neurotoxicity, a mouse model of
PD (Teismann et al. 2003a). Moreover, 1-methyl-4-phenyl-
pyridinium (MPP+), which is extensively used to induce
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dopaminergic cell loss in primary mesencephalic cell cultures
or cell lines (Leonardi and Mytilineou 1998), can induce
COX-2 expression and activity, and application of a COX-2
inhibitor leads to reduced levels of MPP+-induced prosta-
glandin E2 (PGE2) production and subsequent decreased
dopaminergic neurotoxicity in mixed neuron–microglia
cultures (Wang et al. 2005).
Additionally it has been shown, that COX-2 can oxidize
dopamine to reactive dopamine-quinone which has been
implicated in the pathogenesis of PD (Hastings 1995;
Teismann et al. 2003a). Indeed, our previous study has
found that blocking COX-2 leads to a decrease in
dopamine-quinone levels and an attenuation of MPTP-
induced neurodegeneration (Teismann et al. 2003a). Thus,
the neuroprotective effect of COX-2 inhibition appears to
be related to the blockade of COX-2-mediated dopamine
oxidation in PD. A further deleterious consequence of
dopamine-quinone is the accumulation of toxic α-synuclein
protofibrils which are thought to lead to the formation of
Lewy bodies, a pathological hallmark of PD (Periquet et al.
2007; Wilson et al. 2004).
In view of this, we hypothesized that dopamine itself
mediates MPP+-induced dopaminergic neurotoxicity and that
COX-2 modulates dopamine-mediated MPP+-induced neu-
rotoxicity through generation of ROS. To test this hypothesis,
we used an in vitro model of PD by culturing primary ventral
mesencephalic (VM) neurons treated with MPP+. We
examined the effects of reserpine (a dopamine-depleting
agent) and dopamine on MPP+-treated VM toxicity and
apoptosis in tyrosine hydroxylase (TH)-positive neurons.
Moreover, dopamine and MPP+-cotreated cells were further
incubated with COX-2 inhibitors in order to determine
whether the protective effects of COX-2 inhibitors on
dopamine-mediated MPP+-induced neurotoxicity were me-
diated via reduction of reactive oxygen species (ROS).
Materials and methods
Primary midbrain neuron cultures
Mesencephalic dissociated neurons were prepared from the
ventral mesencephalon of E14 rat (Sprague–Dawley) fetus
according to the procedure described (Krieglstein et al. 1995)
with minor modifications. Experimental protocols were in
accordance with Home Office and institutional guidelines.
The ventral mesencephalons from 15 embryos were collected
in calcium–magnesium free Hank’s balanced salt solution
(Invitrogen) containing 5 mM sodium bicarbonate (pH 7.0–
7.2). Cells were dissociated with 0.25% trypsin in Hank’s
balanced salt solution. Dissociation was stopped by addition
of an equal volume of fetal calf serum and 1 mg/ml DNAse
(Roche). Thereafter, tissue was triturated three times with a
wide pore, siliconized Pasteur pipette. Cells were plated on
polyornithine and laminin-coated coverslips at a density of
2.5×105 cells/cm2. Culture medium consisting of Dulbecco’s
modified eagle medium with F12 nutrient mixture (Sigma)
plus 1% N1 mix (Sigma), 10% fetal calf serum (FCS), 2 mM
L-glutamine, 100 U/ml penicillin/streptomycin (Invitrogen),
and 1 μg/ml insulin (Sigma) was supplied at 500 μl/well.
Cells were maintained at 37°C, 5% CO2 for 6 days. The
culture medium was changed after 24 h and then changed
every second day. MPP+ (20 μM; Sigma), dopamine (100 and
250 μM; Sigma), DFU [5,5-dimethyl-3-(3-fluorophenyl)-4-(4-
methylsulphonyl)phenyl-2(5H)-furanone] (10 and 100 nM;
Merck), and ibuprofen (25 and 250 μM; Sigma) were added
on day in vitro (DIV) 4 for 48 h. Cells were pretreated with
reserpine (50 and 500 nM; Sigma) before MPP+.
These preparations yield 95% neurons, with the rest
being primarily astrocytes and a few contaminating micro-
glia cells (Liu and Hong 2003; Takeshima et al. 1994).
Thus, the effects observed from the addition of COX-2
inhibitors are derived mainly from COX-2 expressed by
dopaminergic neurons, as COX-2 is induced in dopaminer-
gic neurons by MPP+ (Wang et al. 2005).
Immunocytochemistry
Cultures were fixed with 4% paraformaldehyde in
phosphate buffered saline (PBS) for 20 min. After
fixation, they were washed with PBS and incubated with
10% goat serum in PBS for 10 min at room temperature.
Cells were washed and incubated over night at 4°C with
a rabbit antibody against tyrosine hydroxylase (TH,
1:200; Chemicon). Immunostaining was visualised with
a cyanine 3 (Cy3, red)-labeled goat anti-rabbit antibody
(1:200; Jackson Immunoresearch) and an Alexa Fluor
488 goat anti-mouse antibody (1:200; Invitrogen). Neg-
ative controls were performed by substitution of non-
immune sera for the primary or secondary antisera.
Coverslips were mounted on glass slides and observed
with a Zeiss Axioplan microscope.
MTT assay
Cell viability was determined by the method of modified 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide
(MTT; Sigma) assay. Cells were plated on 96-well microtiter
plates, and treatment occurred 48 h after plating. Treatment
was then left for another 48 h after which the MTT solution
(5 mg/ml in PBS) was added, and 4 h were allowed for
incubation. Then, cells were solubilised andmixed thoroughly
in 100 μl of dimethyl sulfoxide (DMSO) per well. The
absorption was measured at 570 nm with reference at 670 nm.
Results were expressed as the percentage of the absorbance of
the vehicle-treated control culture wells.
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LDH assay
Lactate dehydrogenase (LDH) enzymatic activity in the
medium was measured using the LDH Cytotoxicity assay
kit (Cayman) according to the manufacturer’s instructions.
LDH is released into the medium upon cell lysis, and the
activity measured in the medium is therefore proportional to
the number of lysed cells. The amount of cell death was
calculated as released LDH/total LDH (value obtained by
lysing all cells with 1% Triton-X100 in the untreated wells).
Results were expressed as the percentage of the vehicle-
treated control culture wells.
Apoptosis assay
Apoptosis was detected by Hoechst 33258 staining (Mo-
lecular Probes). After immunocytochemistry staining, cells
were incubated for 20 min with Hoechst 33258 (2 μg/ml).
Healthy cells were identified from their evenly and
uniformly stained nuclei. Apoptotic cells showed cell
nuclear condensation and/or fragmentation. Apoptotic
nuclei were counted as a percentage of total TH-positive
staining cells.
Reactive oxygen species production
ROS production was detected using the fluorescence probe
carboxy-H2DCFDA (6-carboxy-2′,7′-dichlorodihydrofluores-
cein diacetate). Cells were loaded with H2DCFDA (10 μM)
30 min before the end of the incubation period (48 h). Cells
were washed twice with PBS and fixed with 4% parafor-
maldehyde. Fluorescence (FITC filter) images of cells were
taken immediately using a fluorescence microscope equipped
with a digital camera (DP70, Sony). DCFDA cells were
counted as a percentage of total TH-positive staining cells.
Cell counting
Cell counting of positive stained cells was carried out using
stereology (West et al. 1991). For each well counted, a
similar area was delineated and systematically sampled at
high magnification (×63) from a random start position to
verify cell types and observe apoptosis state in duplicate
fashion. Only cells with distinct immunoreactivity, clear
neuronal shape with a round soma and a nucleus were
counted as TH, or H2DCFDA-positive neurons. To obtain
unbiased counting, slides were coded and cells were scored
blindly without previous knowledge of treatment.
Statistical analysis
All data are presented as means ± SD. One-way analysis of
variance (ANOVA) and Newman–Keuls test were employed
for the comparison among groups, and differences were
considered significant at p<0.05.
Results
Effects of reserpine on MPP+-induced neurotoxicity
and cell apoptosis
The cultures were preincubated with reserpine (50 and
500 nM), a dopamine-depleting agent, for 4 h and then exposed
to MPP+ (20 μM) for 48 h. Cell toxicity was assessed by
LDH release and MTT reduction. As shown in Fig. 1a, a
significant loss of cell viability, as indicated by LDH release
(200% compared to basic levels set at 100%), was observed at
20 μM MPP+ compared to untreated control cells. However,
when the cells were pre-incubated with reserpine (50 and
500 nM), MPP+-induced VM cell toxicity was attenuated
significantly to 143% and 115%, respectively. Reserpine
(500 nM) was even capable of abolishing apoptosis by
MPP+ and restoring cell viability back to normal levels in the
presence of MPP+ (Fig. 1b and c). No cell toxicity or
apoptosis was observed in cells treated with reserpine alone.
Effects of dopamine on MPP+-induced neurotoxicity
and cell apoptosis
Cells were co-treated with MPP+ and dopamine (100 and
250 μM) or dopamine alone for 48 h. Dopamine at 100 μM
did not significantly affect VM cell toxicity or apoptosis in
TH-positive neurons, whilst at a concentration of 250 μM
led to an increase in cell toxicity and apoptosis in TH-
positive neurons compared to untreated control cells
(Fig. 2). Dopamine (250 μM) leads to a decrease in cell
viability to 24% as assessed by MTT assay, while cell
apoptosis was increased to 200% at the same time.
Moreover, MPP+-induced cell toxicity and apoptosis was
increased in the presence of dopamine (Fig. 2b and c), with
apoptosis levels at 309% and cell survival being reduced to
24% in the presence of MPP+ and dopamine (250 μM).
Effects of COX-2 inhibitors on MPP+-induced neurotoxicity
and cell apoptosis
Cells were treated with MPP+ (20 μM), the specific COX-2
inhibitor DFU (10 and 100 nM), or the non-specific COX
inhibitor ibuprofen (25 and 250 μM) for 48 h. As shown in
Fig. 3, DFU attenuated MPP+-induced cell toxicity as
demonstrated by changes in LDH release. DFU (10 nM)
reduced MPP+ induced LDH release from 196% (MPP+-
treated controls) to 149% and MTT measurement was
increased by DFU (10 nM) to 64% compared to 44%
(MPP+ treated controls). Apoptosis in dopaminergic neu-
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rons was lower when cells were treated with DFU (10 nM),
down to 152%, compared to cells which received MPP+
alone. Ibuprofen treatment resulted in similar results as
those observed with DFU (Fig. 4).
Effects of COX-2 inhibitors on dopamine-exacerbated
MPP+-induced neurotoxicity and cell apoptosis
To examine whether dopamine-exacerbated MPP+-induced
cell death is caused by COX-2, either DFU (10 nM) or
ibuprofen (250 μM) was added after treatment with
dopamine (250 μM) and/or MPP+ (20 μM). The combined
treatment of VM cells with MPP+ (20 μM) and dopamine
(250 μM) treatment led to an increase in VM cell toxicity
(LDH release at 318%) (Fig. 5a) and apoptosis among TH-
positive neurons (330%) compared to untreated control
cells set at 100% (Fig. 5c). Also cell viability was reduced
to 23% in the presence of dopamine (250 μM) and MPP+
(20 μM) as measured via MTT assay (Fig. 5b). DFU
Fig. 2 Effects of dopamine on MPP+-induced VM dopaminergic
neurotoxicity and cell apoptosis. MPP+ (20 μM)-treated cells were
incubated with two concentrations (100 and 250 μM) of dopamine. a
LDH release, b MTT assay, and c quantification of apoptosis in TH-
positive neurons were performed 48 h after treatment with MPP+. Data
are expressed as percent of values in untreated control cells and are
means ± S.D. of three independent experiments. All treatments were
performed in duplicate and data expressed were averaged values of all
cells counted in each condition. The results were compared by one-
way ANOVA and Newman–Keuls test. $Significant difference to the
first column (p<0.05 vs. control cells treated with saline), #significant
difference to the first and second column (p<0.05 vs. control cells
treated with saline and vs. saline+dopamine 100 µM), *significant
difference to the first, second, third and fourth columns (p<0.05 vs.
control cells treated with saline, vs. control+dopamine 100 µM, vs.
control+250 µM dopamine and vs. MPP+ alone)
Fig. 1 Effects of reserpine on MPP+-induced ventral mesencephalic
(VM) dopaminergic neurotoxicity and cell apoptosis. MPP+ (20 μM)
treated cells were pre-incubated with two concentrations (50 and
500 nM) of reserpine. a LDH release, b MTT assay, and c
quantification of apoptosis in TH-positive cells were performed at
48 h after treatment with MPP+. Data are expressed as percent of
values of untreated control cells and are means ± SD of three
independent experiments. All treatments were performed in duplicate
and data expressed were averaged values of all cells counted in each
condition. The results were compared by one-way ANOVA and
Newman–Keuls test. #p<0.05 vs. control cells treated with saline, and
50 and 500 nM reserpine, *p<0.05 vs. MPP+ alone. There was no
significant difference between cells treated with saline and 500 nM
reserpine and those treated with MPP+ and 500 nM reserpine
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(100 nM) had an even more pronounced effect on MPP+-
induced toxicity. DFU (100 nM) reduced MPP+-induced
LDH release from 196% (MPP+-treated controls) to 124%
(Fig. 3a) and MTT measurement was increased by DFU
(100 nM) to 77% compared to 44% (MPP+-treated
controls) (Fig. 3b). Apoptosis in dopaminergic neurons
was lower when cells were treated with DFU (100 nM),
down to 128% compared to cells which received MPP+
alone. (Fig. 3c) Ibuprofen treatment resulted in similar
results as those observed with DFU (Fig. 4), but the lower
dose of ibuprofen (25 μM) failed to have any effect on
MPP+-induced apoptosis (Fig. 4c).
MPP+-induced cell toxicity and apoptosis in TH-positive
neurons were substantially increased when dopamine was
added compared to MPP+ alone; however, this was
significantly attenuated by DFU (10 nM) or ibuprofen
(250 μM). LDH release due to the combined treatment of
VM cells with MPP+ and dopamine was reduced to 253%
in the presence of DFU (10 nM) or 268% when co-treated
with ibuprofen (250 μM) (Fig. 5a). Addition of DFU
(10 nM) led to a significant increase of cell viability to 42%,
whereas ibuprofen (250 μM) increased cell viability to 45%
(Fig. 5b). Apoptosis, as observed by counting apoptotic
nuclei due to VM cells treated with MPP+ and dopamine,
was reduced to 240% in the presence of DFU (10 nM) or
233% in the presence of ibuprofen (250 μM) (Fig. 5c).
Treatment with DFU (10 nM) or ibuprofen (250 μM)
did not lead to any significant changes in dopamine-
Fig. 4 Effects of non-specific COX inhibitor ibuprofen on MPP+-
induced VM dopaminergic neurotoxicity and cell apoptosis. MPP+
(20 μM)-treated cells were incubated with two concentrations (25 and
250 μM) of ibuprofen. a LDH release, b MTT assay, and c
quantification of apoptosis among TH-positive cells were performed
at 48 h after treatment with MPP+. Data are expressed as percent of
values of untreated control cells and are means ± S.D. of three
independent experiments. All treatments were performed in duplicate
and data expressed were averaged values of all cells counted in each
condition. The results were compared by one-way ANOVA and
Newman–Keuls test. #p<0.05 vs. control cells treated with saline, 25
and 250 μM ibuprofen; *p<0.05 vs. MPP+ alone
Fig. 3 Effects of specific COX-2 inhibitor DFU on MPP+-induced
VM dopaminergic neurotoxicity and cell apoptosis. MPP+ (20 μM)-
treated cells were incubated with two concentrations (10 and 100 nM)
of DFU. a LDH release, b MTT assay, and c quantification of
apoptosis among TH-positive cells were performed at 48 h after
treatment with MPP+. Data are expressed as percent of values of
untreated control cells and are means ± S.D. of three independent
experiments. All treatments were performed in duplicate and data
expressed were averaged values of all cells counted in each condition.
The results were compared by one-way ANOVA and Newman–Keuls
test. #p<0.05 vs. control cells treated with saline, and 10 and 100 nM
DFU; *p<0.05 vs. MPP+ alone
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induced VM cell toxicity, cell viability or apoptosis
(Fig. 5a, b and c). Photomicrographs demonstrating the
morphology of apoptotic cells in TH-immunoreactive
neurons in untreated control and treated cells are shown
in Fig. 6. Cells exposed to MPP+ or/and dopamine
exhibited a marked increase in nuclear fragmentation in
TH-positive neurons, whereas those cells treated with
DFU displayed a reduction in nuclear fragmentation. In
addition, after treatment with MPP+, the numbers of TH-
positive cells were decreased compared to control cells
(data not shown); however, the numbers of TH-positive
“apoptotic” cells in MPP+-treated cells were still increased
compared to TH-positive “normal” cells. Thus, the
increased apoptotic cell death observed after treatment
with MPP+ is not due to the decreased number of TH-
positive cells.
A total of 301 cells were counted for the control
treatment, with an average of 16.7±1.5 cells per area
counted. Out of these, 20 (or 1.1±0.4 per area) showed
apoptosis (6.6%). There was a significant increase of
apoptotic cells in the presence of dopamine, 289 cells
were counted, out of which 38 showed apoptosis
(13.1%); and in the case of MPP+, 232 cells were
counted, with 31 showing apoptosis (13.4%). The com-
bined treatment of dopamine and MPP+ led to apoptosis in
47 cells out of 214 counted (22%). Addition of DFU
(10 nM) to the combined treatment with dopamine and
MPP+ led to a significant reduction in apoptosis — 39
cells out of 247 counted (15.8%). Also ibuprofen
(250 μM) was able to significantly reduce apoptosis with
34 cells out of 221 counted showing apoptosis (15.4%).
Addition of DFU (10 nM) to dopamine led to a reduction
in the number of apoptotic cells to 27 cells out of 266
counted (10.2%) and, in the case of ibuprofen (250 μM)
26 cells out of 243 counted showed apoptosis (10.7%).
Both values showed no significant difference when
compared to the control treatment where 6.6% or 20 out
of 301 cells showed apoptosis.
Effects of COX-2 inhibitors on dopamine augmented
MPP+-induced ROS production in VM dopaminergic
neurons
To investigate the possible implication of increased ROS
involvment in COX-2 toxicity, DCFDA, an indicator for the
formation of hydroxyl radical (OH•), peroxynitrite, and
hydrogen peroxide was used. Cells treated with dopamine
(250 μM) and MPP+ (20 μM) were incubated either with
Fig. 5 Effects of COX-2 inhibitors on MPP+-induced VM dopami-
nergic neurotoxicity and cell apoptosis in combination with dopamine.
Cells treated with MPP+ (20 μM) or/and dopamine (250 μM) were
incubated with either DFU (10 nM) or ibuprofen (250 μM). a LDH
release, b MTTassay, and c quantification of apoptosis in TH-positive
cells were performed 48 h after treatment with MPP+. Data are
expressed as percent of values of untreated control cells and are means
± SD of three independent experiments. All treatments were
performed in duplicate and data expressed were averaged values of
all cells counted in each condition. The results were compared by one-
way ANOVA and Newman–Keuls test. #p<0.05 vs. control cells; *p<
0.05 vs. MPP+ alone; †p<0.05 vs. MPP+ + dopamine
R
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DFU (10 nM) or ibuprofen (250 μM). The result showed
that MPP+-induced ROS levels in TH-positive cells were
markedly augmented when cells were treated with dopa-
mine compared to cells which received only dopamine
treatment without MPP+.
Numbers of cells with sufficient ROS to produce a signal
were increased from 186% in the presence of MPP+ to
402% in the presence of MPP+ and dopamine. However,
cells co-treated with dopamine and MPP+ incubated in the
presence of either DFU or ibuprofen showed a reduction in the
levels of ROS formation in TH-positive neurons to 308% and
330%, respectively (Fig. 7). No significant difference was
observed in the ROS levels in TH-positive neurons after co-
treatment with dopamine and DFU/ibuprofen. Photomicro-
graphs demonstrating the DCFDA staining in TH-
immunoreactive neurons in untreated control and treated
Fig. 6 Imaging of apoptotic/TH staining. Imaging was performed
48 h after treatment with MPP+. Hoechst 33342 staining was carried
out to visualize the apoptotic cells. Condensed or fragmented nuclei
that were brightly stained were considered to be from apoptotic cells.
Apoptosis: blue fluorescence; TH: red fluorescence. Co-localization of
apoptosis and TH was observed by merging red and blue fluorescence
signals. Scale bar, 10 μm
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cells are shown in Fig. 8. Cells exposed to MPP+ or/and
dopamine displayed an increase in TH-positive neuronal
staining with DCFDA, whereas those cells treated with DFU
in combination with MPP+ and dopamine were able to
reduce measureable ROS generation.
Discussion
The findings of this study reveal that reserpine significantly
reduced VM dopaminergic neurotoxicity induced by MPP+,
whereas dopamine increased the MPP+-induced VM cell
toxicity and apoptosis in TH-positive neurons. Despite our
own hypothesis we were only able to demonstrate an
additive effect of dopamine on MPP+-induced toxicity
instead of any synergism.
Herein we demonstrate that dopamine added to a
neurotoxin increases cellular apoptosis in an additive
manner and ROS formation can be attenuated by the
addition of a COX-2 inhibitor. Although the exact mech-
anism is unknown, three possible mechanisms of action can
be attributed to the observed effects: the ability of COX-2
to generate ROS (Smith et al. 2000), the ability of COX-2
generated ROS, with dopamine itself inside the dopaminergic
neurons to generate dopamine-quinone (Hastings 1995;
Teismann et al. 2003a), and, finally, the ability of COX-2
to produce neurotoxic PGE2 (O’Banion 1999).
Inhibition of COX-2 by DFU or ibuprofen significantly
attenuated the effect obtained with dopamine given in
addition to MPP+ with respect to cell toxicity, apoptosis
and ROS production. Inhibition of COX-2 appears to be
through inhibition of ROS production. It also has been
suggested that dopamine plays a key role in the demise of
nigrostriatal neurons since dopamine containing neurons
die in PD.
In this study, we demonstrated that dopamine depletion
by treatment with reserpine protected against MPP+-
induced cell toxicity and apoptosis in VM dopaminergic
neurons. This indicates that dopamine plays a role in the
toxicity of MPP+ in VM dopaminergic neurons. Moreover,
the mechanism of dopamine neurotoxicity is highly linked
to increased production of oxidizing species, which has
been implicated in the pathogenesis of PD (Liang et al.
2005; Teismann et al. 2003a). Several reports have shown
that dopamine can be oxidized to dopamine-quinone, which
is toxic to cells (Blum et al. 2001; Dryhurst 2001). A study
has also shown that treatment with dopamine of HEK293
cells or rat striatal neuronal cultures induces apoptosis
through a mechanism dependent on ROS (Luo et al. 1998).
Thus, identification of the cellular factor that could
facilitate or induce oxidation of dopamine would provide an
attractive strategy in the understanding of the pathogenesis
of dopaminergic degeneration in PD. MPP+ possesses two
opposing effects, on one hand it leads to an extensive
release of dopamine and on the other hand MPP+ inhibits
monamine oxidase (MAO)-A (Feuerstein et al. 1988), with
MAO-B only slightly inhibited (Fritz et al. 1985), thereby
counteracting the oxidation of dopamine. A process by
which dopamine oxidation still could occur is via COX-2,
as COX-2 itself can lead to the generation of ROS (Smith et
al. 1991) and has been shown to react with dopamine to
form dopamine-quinone (Teismann et al. 2003a).
L-Dihydroxyphenylalanine (L-DOPA) which is used to
relieve parkinsonian symptoms is converted by neuronal
aromatic L-amino acid decarboxylase into dopamine after
administration. This could lead to increased ROS formation
as systemic administration of L-DOPA has been shown to
significantly increase nigral hydroxyl radical production in
the freely moving rat (Spencer Smith et al. 1994).
Additionally, rats lesioned with 6-hydroxy-dopamine (6-
OHDA) showed less generation of ROS and lesion volume
when subjected to malonate treatment using microdialysis
(Ferger et al. 1999). Intrastriatal malonate injections
generate selective neuronal cell death similar to that seen
in transient ischemia or Huntington’s disease. Herein
malonate was applied via the probe to study synaptic
dopamine release and the generation of hydroxyl (•OH)
radicals by microdialysis.
On the other hand several studies have demonstrated
that neither genetic nor pharmacologic dopamine deple-
Fig. 7 Effects of COX-2 inhibitors on dopamine augmented MPP+-
induced ROS production in VM dopaminergic neurons. Cells treated
with MPP+ (20 μM) and/or dopamine (250 μM) were incubated with
either DFU (10 nM) or ibuprofen (250 μM). Quantification of ROS
formation in TH-positive cells was performed at 48 h after treatment
with MPP+. Data are expressed as percent of values in untreated
control cells and are means ± SD of three independent experiments.
All treatments were performed in duplicate and data expressed were
averaged values of all cells counted in each condition. The results
were compared by one-way ANOVA and Newman–Keuls test. #p<
0.05 vs. control cells; *p<0.05 vs. MPP+ alone; †p<0.05 vs. MPP+ +
dopamine. Scale bar, 20 μm
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tion protects the nigrostriatal pathway from acute MPTP
toxicity in mice (Hasbani et al. 2005). There are several
lines of evidence in vivo as well as in vitro, supporting
this hypothesis (Hastings et al. 1996; Rabinovic et al.
2000). Moreover, L-DOPA taken by healthy patients did
not cause any reduction in numbers of nigral neuronal
cells nor did it promote PD (Quinn et al. 1986; Rajput et
al. 1997). L-DOPA is then converted by neuronal aromatic
L-amino acid decarboxylase into dopamine, thereby
restoring dopamine levels in surviving neurons. However
these cell populations continue to die despite the L-DOPA
treatment (Basma et al. 1995).
Studies have shown that a COX-1 inhibitor failed to
antagonize the MPTP-induced striatal dopamine depletion
in mice (Aubin et al. 1998). Ablation of the COX-1 gene in
knockout mice failed to produce neuroprotection on MPTP-
elicited toxicity in contrast to COX-2 knockout mice (Feng
et al. 2002; Teismann et al. 2003a). Therefore, COX-2 plays
Fig. 8 Imaging of MPP+-induced ROS production in VM dopami-
nergic neurons. Imaging of DCFDA/TH staining were performed at
48 h after treatment with MPP+. ROS production was detected by
DCFDA staining. DCFDA: green fluorescence; TH: red fluorescence.
Co-localization of DCFDA and TH was observed by merging red and
green fluorescence signals. DCFDA 6-carboxy-2′,7′-dichlorodihydro-
fluorescein diacetate; Scale bar, 20 μm
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a major role in mediating MPP+-induced VM neurotoxicity
and VM dopaminergic cell apoptosis. Additionally, in the
present study, COX-2 inhibitors do not prevent toxicity of
dopamine alone, and consistently inhibit only the “MPP+
portion” of toxicity in the co-stress condition, leaving intact
the same degree of cell death observed with dopamine
alone.
This suggests that COX-2 may only be relevant when
MPP+ is applied and COX-2 inhibition does not affect
normal ROS formation due to dopamine turnover. This
also suggests that dopamine itself leads to radical
formation, but a healthy system is capable of dealing with
these low levels of ROS. In the case of a dysregulation, as
seen in PD, dopamine becomes a substrate for activated
COX-2 and therefore a source of ROS, leading to cell
death.
In our hands DFU showed a major effect already at very
low concentrations (10 nM), whereas similar results could
only be obtained with a higher dose of ibuprofen (250 μM).
DFU alone is a very potent COX-2 inhibitor, with the
highest specificity for COX-2 inhibition (1,000-fold selec-
tivity for COX-2 vs. COX-1). Also, the ED50 of DFU vs.
COX-2 is higher than that of ibuprofen (Riendeau et al.
1997), which very likely resulted in the low effective dose
of DFU as seen in this study.
It is widely accepted that inflammation and oxidative
stress are interrelated. Oxidative stress can increase
inflammatory activity and, conversely, inflammation is
known to cause oxidative stress (Liao et al. 2007;
Madrigal et al. 2003; Teismann et al. 2003a). It is also
evident that COX-2 plays a detrimental role in stimulation
of an inflammatory process following neuronal death.
PGE2, a key product of COX-2, is the principal pro-
inflammatory prostanoid and PGE2 levels were shown to
increase in MPTP-treated mice as well as after neurotoxic
insult in mixed and enriched mesencephalic cultures
(Teismann et al. 2003a; Wang et al. 2005). Future studies
are needed to clarify whether PGE2, generation of
dopamine-quinone or a combination of both effects are
responsible for the selective vulnerability of dopaminergic
neurons to COX-2-induced oxidative stress.
In summary, dopamine appears to be a component of
MPP+-induced toxicity in VM dopaminergic neurons. The
protective effects of COX-2 inhibitors on MPP+-induced
neurotoxicity in the presence of dopamine and cell
apoptosis may be mediated via reduction of ROS.
Dopamine toxicity seems to be driven mainly by conver-
sion through COX-2 in the presence of MPP+ and thus
might be one factor responsible for the specific cell death
of dopaminergic neurons as seen in PD. Our observations
confirm that inhibition of COX-2 activity is a valid
strategy to delay or prevent the loss of dopaminergic
neurons in PD.
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